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Tamoxifen has long been considered the endocrine
therapy of choice for the treatment of women with
hormone-sensitive breast cancer. The most recently
published overview of adjuvant tamoxifen trials showed
that in patients with hormone receptor-positive disease,
the odds of recurrence and death were reduced by 47%
and 26%, respectively, following about 5 years of ther-
apy with tamoxifen [1]. Despite it is proven eﬀectiveness,
tamoxifen is associated with an increased risk of en-
dometrial cancer, uterine sarcoma and thromboembolic
disorders [2,3].
In postmenopausal women, the major source of
oestrogen is from peripheral aromatisation of andro-
gens; the rate-limiting step catalysed by aromatase
enzyme. Anastrozole is a third generation aromatase
inhibitor and has no partial oestrogenic activity like
tamoxifen. Anastrozole has been established to be
eﬀective and well tolerated as ﬁrst-line therapy for
treatment of breast cancer [4]. The Armidex, tamoxi-
fen, alone or in combination (ATAC) trial (N = 9366)
is a large international, randomised, double-blind,
multicentre study that compared the eﬃcacy of anas-
trozole (N = 3125) against tamoxifen (N = 3116) or a
combination of both drugs (N = 3125) [5]. The trial
was designed to answer three important questions: (1)
Is anastrozole at least as eﬀective as tamoxifen in
postmenopausal patients with early breast cancer? (2)
Does anastrozole oﬀer any safety or eﬃcacy advan-
tage over tamoxifen in this subset of patients? (3)
Could the combination of anastrozole plus tamoxifen
oﬀer additional eﬃcacy or safety beneﬁts over
tamoxifen alone? The initial data with a median fol-
low-up of 33 months demonstrated that anastrozole
signiﬁcantly prolonged disease-free survival compared
with tamoxifen in overall population (Hazard Ratio
0.83; 95% Conﬁdence Interval 0.71–0.96, P = 0.013)
with disease-free survival in patients receiving the
combination not being signiﬁcantly diﬀerent from
those receiving tamoxifen alone. Disease-free survival
was further improved in patients with hormone re-
ceptor-positive disease; 84% of patients in the study
population. There were no diﬀerences in patients with
hormone receptor-negative disease between the three
arms of the study. At a median follow-up of 47
months, the primary endpoint, disease-free survival
was again signiﬁcantly longer for patients who re-
ceived anastrozole alone compared with those who
received tamoxifen alone (Hazard Ratio 0.86; 95%
Conﬁdence Interval 0.76–0.99; P = 0.03) [6]. There
were no signiﬁcant diﬀerences in disease-free survival
between tamoxifen and the combination arm. These
data conﬁrmed the results of the initial analysis.
Relative Risk reduction was greater among patients
with hormone receptor-positive disease. Hazard Ratio
was 0.82 (95% Conﬁdence Interval 0.70–0.96; P =
0.014) for anastrozole versus tamoxifen. Absolute
diﬀerences in disease-free survival in favour of anas-
trozole increased over time.
At a median follow-up of 33 months, there was a
signiﬁcant reduction in primary contralateral breast
cancer as a ﬁrst event in the anastrozole group com-
pared with tamoxifen (Odds Ratio 0.42; 95% Conﬁdence
Interval 0.22–0.79; P = 0.007). This reduction continued
to be seen in anastrozole group after an immediate fol-
low-up of 47 months and was statistically signiﬁcant in
the subgroup with hormone receptor-positive disease
compared with tamoxifen, odds were reduced by 38% in
overall population. Odds Ratio being 0.62 (95% Conﬁ-
dence Interval 0.38–1.02; P = 0.06), and by 44% in the
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hormone receptor-positive subgroup, Odds Ratio 0.56
(95% Conﬁdence Interval 0.32–0.98; P = 0.04). Initial
and updated safety analysis have shown that anastrozole
therapy was associated with a signiﬁcantly reduced in-
cidence of hot ﬂashes, vaginal bleeding, vaginal dis-
charge, endometrial malignancies, ischaemic cerebral
vascular events, venous thromboembolic events includ-
ing deep vein thrombosis. Musculo-skeletal disorders
and fractures were increased with anastrozole compared
with tamoxifen. The Relative Risk data demonstrate
that beneﬁts from anastrozole were maintained with
longer follow-up and the Relative Risk of fracture or
musculo-skeletal disorders were unchanged, and did not
worsen over time [6,7].
The results of the ATAC trial demonstrate the su-
periority of anastrozole over tamoxifen and conﬁrmed
that anastrozole signiﬁcantly prolonged both disease-
free survival and time-to-recurrence. Anastrozole treat-
ment was also associated with a signiﬁcant reduction in
the risk of contralateral breast cancer compared with
tamoxifen in postmenopausal patients with hormone
receptor-positive early stage breast cancer. The absolute
beneﬁts of anastrozole compared with tamoxifen con-
tinued to increase over time and are expected to result in
improvements in overall survival after additional follow-
up. These data support the use of anastrozole over ta-
moxifen in the treatment of postmenopausal women
with hormone-sensitive early breast cancer, as the
overall therapeutic index of anastrozole is more fa-
vourable than tamoxifen.
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